Parmar H, Phillips R H, Lightman S L, Edwards L, Allen L, Schally A V
Lancet. 1985 Nov 30;2(8466):1201-5. doi: 10.1016/s0140-6736(85)90739-1.
Safety and efficacy of a slow-release formulation of D-Trp-6-luteinising-hormone-releasing-hormone (D-Trp-6-LHRH) microcapsules were compared with orchidectomy in the initial treatment of advanced prostatic carcinoma. 41 patients were randomly assigned to D-Trp-6-LHRH and 38 to orchidectomy. Suppression of testosterone and reduction in prostatic acid phosphatase levels were similar in both groups. 87% of patients in the D-Trp-6-LHRH group and 81% in the orchidectomy group responded to treatment or showed no deterioration. Side-effects related to the decrease in testosterone were similar in both groups. 3 patients given D-Trp-6-LHRH had a disease "flare" in the first ten days of treatment which resolved completely when testosterone fell to castrate levels. Results of psychological assessment were similar in both groups before treatment, and on follow-up there was a weak trend towards decreased psychological morbidity in the hormone group. The slow-release preparation of D-Trp-6-LHRH microcapsules offers an important alternative in the management of advanced prostatic carcinoma.
在晚期前列腺癌的初始治疗中,比较了D-色氨酸-6-促黄体生成激素释放激素(D-Trp-6-LHRH)微胶囊缓释制剂与睾丸切除术的安全性和有效性。41例患者被随机分配至D-Trp-6-LHRH组,38例患者被分配至睾丸切除术组。两组患者的睾酮抑制和前列腺酸性磷酸酶水平降低情况相似。D-Trp-6-LHRH组87%的患者和睾丸切除术组81%的患者对治疗有反应或病情未恶化。两组与睾酮降低相关的副作用相似。3例接受D-Trp-6-LHRH治疗的患者在治疗的前10天出现疾病 “突发”,当睾酮降至去势水平时完全缓解。治疗前两组的心理评估结果相似,随访时激素组心理发病率有轻微下降趋势。D-Trp-6-LHRH微胶囊缓释制剂为晚期前列腺癌的治疗提供了一种重要的替代方法。